natgillin/translations-raw huggingface dataset:
At week 104, 8 subjects had progressed to a score of bilateral Grade 2 on spinal X-ray according to the modified New York Radiological Grade, indicative of axial spondyloarthropathy. 
Po 104 tednih je 8 preskušancev napredovalo do stopnje 2 obojestransko, merjene z rentgenskim slikanjem hrbtenice, kar po spremenjenih newyorških merilih za radiološko oceno kaže na aksialno spondilartropatijo.
Needle safety shield disappears inside the pen 
varnostni ščit igle izgine v peresnik
The safety and efficacy of LIFMIOR were assessed in a two-part study in 69 children with polyarticular-course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset types (polyarthritis, pauciarthritis, systemic onset). 
Varnost in učinkovitost zdravila LIFMIOR je bila ugotovljena v dvodelni študiji pri 69 otrocih s poliartikularnim potekom juvenilnega idiopatskega artritisa z različnimi tipi nastopa bolezni (poliartritis, oligoartritis, sistemski nastop).
Malignancies and lymphoproliferative disorders 
Maligne in limfoproliferativne bolezni
After cleaning, do not touch the stopper with your hands or allow it to touch any surface. 
Po čiščenju se ga ne smete več dotikati z rokami; pazite tudi, da se z njim ne dotaknete drugih površin.
Each new injection should be given at least 3 cm from an old site. 
Vsako naslednjo injekcijo morate dati vsaj 3 cm od mesta prejšnje injekcije.
Evidence of efficacy for the once weekly dosing regimen in this patient population has been based on data from the study in patients with ankylosing spondylitis. 
Pri tej skupini bolnikov dokaz učinkovitosti režima odmerjanja enkrat na teden temelji na podatkih iz študije pri bolnikih z ankilozirajočim spondilitisom.
Such patients should be investigated urgently, including full blood count; if blood dyscrasias are confirmed, LIFMIOR should be discontinued. 
Take bolnike je treba nemudoma pregledati, vključno s pregledom celotne krvne slike, in v primeru krvne diskrazije prekiniti zdravljenje s tem zdravilom.
LIFMIOR N = 138 
Zdravilo LIFMIOR N = 138
• if the child you are caring for is allergic to etanercept or any of the other ingredients of LIFMIOR (listed in section 6). 
če je otrok, za katerega skrbite, alergičen na etanercept ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
Avoid areas with scars or stretch marks. 
Izogibajte se območij z brazgotinami ali strijami.
In subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5% of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with psoriasis, 9.7% of subjects with paediatric psoriasis, and 4.8% of subjects with juvenile idiopathic arthritis. 
Pri bolnikih, ki so jih v kliničnih preskušanjih zdravili z etanerceptom v odobrenih odmerkih do 12 mesecev, je bila kumulativna pogostnost protiteles proti etanerceptu približno 6 % pri bolnikih z revmatoidnim artritisom, 7,5 % pri bolnikih s psoriatičnim artritisom, 2 % pri bolnikih z ankilozirajočim spondilitisom, 7 % pri bolnikih s psoriazo, 9,7 % pri bolnikih z otroško psoriazo in 4,8 % pri bolnikih z juvenilnim idiopatskim artritisom.
Your doctor will decide how long you should take LIFMIOR and whether retreatment is needed based on your response. 
Zdravnik bo na podlagi vašega odziva na zdravilo določil, koliko časa morate uporabljati zdravilo LIFMIOR in ali je potrebno ponovno zdravljenje.
Tell the doctor if the child develops any abdominal cramps and pain, diarrhoea, weight loss or blood in the stool. 
Povejte zdravniku, če se pri otroku pojavijo krči v trebuhu in bolečine, driska, hujšanje ali kri v blatu.
Fold the paper cover back over the tray and place the carton containing any remaining pre-filled syringes back into the refrigerator. 
Papirnato plast pretisnega omota prepognite nazaj in odložite škatlo s preostalimi napolnjenimi injekcijskimi brizgami nazaj v hladilnik.
You or the child should not use LIFMIOR with medicines that contain the active substance anakinra or abatacept. 
Zdravila LIFMIOR vi ali otrok ne smete jemati skupaj z zdravili, ki vsebujejo učinkovino anakinro ali abatacept.
Long-term safety of LIFMIOR monotherapy (n=103), LIFMIOR plus methotrexate (n=294), or methotrexate monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18 years with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of age. 
Dolgoročno varnost zdravljenja z zdravilom LIFMIOR v monoterapiji (n = 103), zdravljenja z zdravilom LIFMIOR v kombinaciji z metotreksatom (n = 294) ali zdravljenja z metotreksatom v monoterapiji (n = 197) so ovrednotili za obdobje do 3 let na osnovi registra 594 otrok, starih od 2 do 18 let, z juvenilnim idiopatskim artritisom.
There is no apparent pharmacokinetic difference between males and females. 
Med farmakokinetiko zdravila pri moških in ženskah ni bistvenih razlik.
• Holding the glass barrel of the syringe (not the white collar) in one hand, and the vial adaptor (not the vial) in the other, connect the syringe to the vial adaptor by inserting the tip into the opening and turn clockwise until completely secured (see Diagram 7). 
Z držanjem steklenega dela brizge (ne belega omota) v eni roki in adapterja viale (ne same viale) v drugi brizgo spojite z adapterjem tako, da vstavite njeno konico v odprtino na adapterju in jo zavrtite v smeri urnega kazalca, dokler se ne ustavi (glejte sliko 7).
One rheumatoid arthritis patient mistakenly self-administered 62 mg LIFMIOR subcutaneously twice weekly for 3 weeks without experiencing undesirable effects. 
En bolnik z revmatoidnim artritisom si je pomotoma subkutano injiciral 62 mg zdravila LIFMIOR 2-krat tedensko 3 tedne, pri tem pa ni prišlo do pojava kakršnegakoli neželenega učinka.
Autoantibody formation Treatment with LIFMIOR may result in the formation of autoimmune antibodies (see section 4.8). 
Zdravljenje z zdravilom LIFMIOR lahko sproži nastajanje avtoimunskih protiteles (glejte poglavje 4.8).
• Hold the vial firmly on the flat surface with one hand. 
Na ravni površini z eno roko čvrsto primite vialo.
These include rare reports of pancytopenia and very rare reports of aplastic anaemia. 
Ta vključujejo tudi redke primere pancitopenije in zelo redke primere aplastične anemije.
Several adverse events were reported more commonly in 69 juvenile idiopathic arthritis patients receiving 3 months of LIFMIOR compared to the 349 adult rheumatoid arthritis patients. 
Nekateri neželeni učinki so bili pogosteje opaženi pri 69 bolnikih z juvenilnim idiopatskim artritisom, ki so zdravilo LIFMIOR prejemali 3 mesece, kot pri 349 odraslih bolnikih z revmatoidnim artritisom.
Physicians should use caution when using LIFMIOR in patients who also have moderate to severe alcoholic hepatitis. 
Zdravniki naj bodo pazljivi, kadar uporabljajo zdravilo LIFMIOR pri bolnikih, ki imajo tudi zmeren do hud alkoholni hepatitis.
Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by TNF. 
Mnogo sprememb sklepov pri revmatoidnem artritisu in ankilozirajočem spondilitisu ter sprememb na koži pri psoriazi v plakih posredujejo vnetne molekule, povezane v mrežo, ki jo nadzira TNF.
• Wegener's granulomatosis: LIFMIOR is not recommended for the treatment of Wegener's granulomatosis, a rare inflammatory disease. 
Wegenerjeva granulomatoza: Zdravilo LIFMIOR ni priporočljivo za zdravljenje redke vnetne bolezni Wegenerjeve granulomatoze.
LIFMIOR in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. 
Zdravilo LIFMIOR je v kombinaciji z metotreksatom indicirano za zdravljenje zmernega do hudega aktivnega revmatoidnega artritisa pri odraslih, kadar odziv na zdravljenje z imunomodulirajočimi antirevmatičnimi zdravili, vključno z metotreksatom (če ta ni kontraindiciran), ni zadosten.
LIFMIOR powder for solution must be reconstituted in 1 ml of solvent before use (see section 6.6). 
Pred uporabo je treba LIFMIOR prašek za raztopino za injiciranje rekonstituirati v 1 ml vehikla (glejte poglavje 6.6).
The primary measure of efficacy (ASAS 20) was a ≥20% improvement in at least 3 of the 4 Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain, BASFI, and inflammation) and absence of deterioration in the remaining domain. 
Primarno merilo učinkovitosti (ASAS 20) je bilo  20 % izboljšanje pri vsaj 3 od 4 domen lestvice Ocenjevanje pri ankilozirajočem spondilitisu (ASAS - Assessment in Ankylosing Spondylitis) (bolnikova splošna ocena, bolečina v hrbtenici, BASFI in vnetje) ter odsotnost poslabšanja pri četrti domeni.
The differences in TSS and JSN were not statistically significant between methotrexate and LIFMIOR 25 mg. 
Razlike v ocenah TSS in JSN med metotreksatom in 25 mg zdravila LIFMIOR niso bile statistično pomembne.
In adults (aged 18 and over), LIFMIOR can be used for moderate or severe rheumatoid arthritis, psoriatic arthritis, severe axial spondyloarthritis including ankylosing spondylitis, and moderate or severe psoriasis - in each case usually when other widely used treatments have not worked well enough or are not suitable for you. 
Pri odraslih (starih 18 let in več) se zdravilo LIFMIOR lahko uporablja pri zdravljenju zmernega ali hudega revmatoidnega artritisa, psoriatičnega artritisa, hudega aksialnega spondilartritisa, vključno z ankilozirajočim spondilitisom, in zmerne ali hude luskavice - v vseh primerih običajno šele po neuspešnem zdravljenju z drugimi običajnimi oblikami zdravljenja, ali če te oblike zdravljenja za vas niso primerne.
Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. 
Zdravljenje poliartritisa (pozitivnega ali negativnega za revmatoidni faktor) in razširjenega oligoartritisa pri otrocih in mladostnikih, starih 2 leti ali več, ki so se nezadostno odzvali na zdravljenje z metotreksatom ali ga niso prenašali.
The primary efficacy endpoint in all four studies was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks. 
Primarni opazovani dogodek učinkovitosti v vseh štirih študijah je bil tisti delež bolnikov v vsaki zdravljeni skupini, ki je po 12 tednih dosegel PASI 75 (tj. vsaj 75 % izboljšanje indeksa PASI - Psoriasis Area and Severity Index; indeks površine in izrazitosti psoriaze - v primerjavi z izhodiščem).
Withdrawing the LIFMIOR solution from the vial f. 
Jemanje raztopine zdravila LIFMIOR iz viale f.
Clean the injection site with the alcohol swab using a circular motion, and allow it to dry. 
Mesto injiciranja s krožnim gibom obrišite z alkoholno blazinico in pustite, da se posuši.
4 vials of powder 
4 viale s praškom
Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the foetus or neonatal rat due to etanercept. 
Študije toksičnosti za razvoj, ki so jih opravili na podganah in kuncih, niso pokazale nobenih znakov škodljivih učinkov etanercepta na zarodke ali novorojene podgane.
If you have any questions, please talk to a doctor, nurse or pharmacist who is familiar with LIFMIOR. 
Če imate kakršnakoli vprašanja, se posvetujte z zdravnikom, medicinsko sestro ali farmacevtom, ki dobro poznajo zdravilo LIFMIOR.
†Please see sub-section ‘Undesirable effects in paediatric patients with juvenile idiopathic arthritis' above. 
*glejte Opis izbranih neželenih učinkov v nadaljevanju prosimo, glejte podpoglavje ''Neželeni učinki pri otrocih z juvenilnim idiopatskim artritisom'' zgoraj
The efficacy of LIFMIOR was assessed in a randomised, double-blind, placebo-controlled study in 205 patients with psoriatic arthritis. 
Učinkovitost zdravila LIFMIOR je bila ocenjena v randomizirani, dvojno slepi in s placebom nadzorovani študiji pri 205 bolnikih s psoriatičnim artritisom.
Patients with a significant exposure to varicella virus should temporarily discontinue LIFMIOR therapy and be considered for prophylactic treatment with Varicella Zoster Immune Globulin. 
Bolniki, ki so zelo izpostavljeni virusu noric, naj začasno prekinejo zdravljenje z zdravilom LIFMIOR, v poštev pa pridejo tudi za profilaktično zdravljenje z imunoglobulinom proti virusu varicella-zoster.
Combining the results of controlled clinical trials, more cases of NMSC were observed in patients receiving LIFMIOR compared with control patients, particularly in patients with psoriasis. 
Pri združevanju rezultatov nadzorovanih kliničnih preskušanj so opazili več primerov NMSC pri bolnikih, ki so prejemali zdravilo LIFMIOR, kot pri kontrolnih bolnikih, še zlasti pri bolnikih s psoriazo.
4 years. 
4 leta
Adjusted mean change from baseline was 3.8 for LIFMIOR treated (n=95) versus 0.8 for placebo treated (n=105) patients (p<0.001). 
Prilagojena povprečna sprememba od izhodišča je bila 3,8 pri bolnikih, zdravljenih z zdravilom LIFMIOR (n = 95), in 0,8 pri bolnikih, ki so prejemali placebo (n = 105) (p < 0,001).
For patients who received 50 mg once weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI 75 at week 24. 
Pri bolnikih, ki so dobivali 50 mg enkrat na teden ves čas študije, so se odzivi glede učinkovitosti še naprej izboljševali, tako da je v 24. tednu PASI 75 doseglo 71 % bolnikov.
It is recommended that the conduct of these tests should be recorded in the patient's alert card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised. 
Zdravnike predpisovalce opominjamo na nevarnost lažno negativnih rezultatov tuberkulinskega kožnega testa, še zlasti pri bolnikih, ki so hudo bolni ali imunoinkompetentni.
There were no differences in rates of infection among patients treated with LIFMIOR and those treated with placebo for plaque psoriasis in placebo-controlled trials of up to 24 weeks duration. 
V stopnjah pogostnosti okužb med bolniki, zdravljenimi z zdravilom LIFMIOR, in tistimi, ki so prejemali placebo za zdravljenje psoriaze v plakih, v preskušanjih, nadzorovanih s placebom, ki so trajala do 24 tednov, ni bilo razlik.
Serious infections (including pneumonia, cellulitis, arthritis bacterial, sepsis and parasitic infection)* 
resne okužbe (vključno s pljučnico, celulitisom, bakterijskim artritisom, sepso in parazitsko okužbo)*
These infections were due to bacteria, mycobacteria, fungi, viruses and parasites (including protozoa). 
Te okužbe so povzročale bakterije, mikobakterije, glivice, virusi in paraziti (vključno s protozoji).
• Signs of autoimmune reactions (where antibodies are made that may harm normal tissues in the body) such as pain, itching, weakness, and abnormal breathing, thinking, sensation, or vision 
• znaki avtoimunskih reakcij (reakcije, pri katerih se tvorijo protitelesa, ki lahko poškodujejo normalna telesna tkiva), kot so bolečina, srbenje, oslabelost, težave z dihanjem, motnje mišljenja, zaznavanja ali vida;
Please tell your doctor if you or the child in your care have a history of alcohol abuse. 
Povejte zdravniku, če imate vi ali otrok, za katerega skrbite, zgodovino zlorabe alkohola.
In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with LIFMIOR developed injection site reactions compared with 3.4% of placebo-treated patients during the first 12 weeks of treatment. 
V nadzorovanih preskušanjih bolnikov s psoriazo v plakih so se reakcije na mestu injiciranja v prvih 12 tednih zdravljenja pojavile pri približno 13,6 % bolnikov, zdravljenih z zdravilom LIFMIOR, in pri 3,4 % bolnikov, ki so dobivali placebo.
Worsening of cardiac failure congestive (see section 4.4) 
Srčne bolezni poslabšanje kongestivnega srčnega popuščanja (glejte poglavje 4.4)
Push the open end of the pen firmly against the skin, so that the needle safety shield is pushed completely inside of the pen. 
Pritisnite odprti konec peresnika čvrsto navzdol proti koži, da varnostni ščit igle ne bo več viden.
From the start of part 2, the median time to flare was ≥ 116 days for patients who received LIFMIOR and 28 days for patients who received placebo. 
Od začetka drugega dela študije je bil mediani čas do ponovnega izbruha bolezni  116 dni pri bolnikih na zdravilu LIFMIOR in 28 dni pri bolnikih na placebu.
This combination has not demonstrated increased clinical benefit; such use is not recommended (see section 4.4). 
Ta kombinacija ni pokazala povečane klinične koristi, zato njena uporaba ni priporočljiva (glejte poglavje 4.4).
Patients were observed off treatment for the occurrence of rebound (PASI ≥150% of baseline) and for the time to relapse (defined as a loss of at least half of the improvement achieved between baseline and week 24). 
Bolnike so brez zdravljenja spremljali glede preobratnih znakov (PASI  150 % izhodiščnega) in časa do recidiva (opredeljenega kot izginotje vsaj polovice izboljšanja, doseženega med izhodiščem in 24. tednom).
The long-term safety of LIFMIOR in combination with other disease-modifying antirheumatic drugs (DMARD) has not been established. 
Varnost dolgotrajnega kombiniranega zdravljenja z zdravilom LIFMIOR in drugimi imunomodulirajočimi antirevmatičnimi zdravili (DMARD - Disease-Modifying AntiRheumatic Drugs) ni bila ugotovljena.
0.8†,φ a: Patients who did not complete 12 months in the study were considered to be non-responders. 
HAQ v izhodišču po 52 tednih a: Bolniki, ki v študiji niso sodelovali 12 mesecev, so bili obravnavani kot neodzivni.
Undesirable effects in paediatric patients with plaque psoriasis In a 48-week study in 211 children aged 4 to 17 years with paediatric plaque psoriasis, the adverse events reported were similar to those seen in previous studies in adults with plaque psoriasis. 
Neželeni učinki pri pediatričnih bolnikih s psoriazo v plakih V 48-tedenski študiji pri 211 otrocih, starih 4 do 17 let, z otroško psoriazo v plakih so bili poročani neželeni učinki podobni tistim, ki so jih opažali v predhodnih študijah pri odraslih s psoriazo v plakih.
Ankylosing Spondylitis Response 
Odziv ankilozirajočega spondilitisa
LIFMIOR should be discarded if not used within four weeks after removal from the refrigerator. 
Zdravilo LIFMIOR zavrzite, če ga ne porabite v štirih tednih po odvzemu iz hladilnika.
After 12 weeks of treatment, patients in the placebo group began treatment with blinded LIFMIOR (25 mg twice a week); patients in the active treatment groups continued to week 24 on the dose to which they were originally randomised. 
Po 12 tednih zdravljenja so bolniki v skupini s placebom začeli slepo zdravljenje z zdravilom LIFMIOR (25 mg dvakrat na teden), bolniki v skupinah z aktivnim zdravljenjem pa so do 24. tedna nadaljevali z odmerkom, na katerega so bili prvotno randomizirani.
Histiocytosis haematophagic (macrophage activation syndrome)* 
hematofagna histiocitoza (sindrom aktivacije makrofagov)*
Be careful not to bend or twist the cover during removal to avoid damage to the needle. 
Pazite, da med odstranjevanjem pokrovčka le-tega ne ukrivite ali zavihate, da ne poškodujete igle.
Radiographs of hands and wrists were obtained at baseline and months 6, 12, and 24. 
Radiografijo dlani in zapestja so opravili v izhodišču in v 6., 12. in 24. mesecu.
In a double blind, placebo controlled, randomised clinical study in adult patients with psoriatic arthritis 184 patients also received a multivalent pneumococcal polysaccharide vaccine at week 4. 
V dvojno slepi s placebom nadzorovani randomizirani klinični študiji pri odraslih bolnikih s psoriatičnim artritisom je 184 bolnikov v 4. tednu dobilo tudi multivalentno polisaharidno cepivo proti pnevmokokom.
TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on cross-linking of cell surface TNFRs. 
TNF in limfotoksin obstajata pretežno v obliki homotrimerov, njuna biološka aktivnost pa je odvisna od navzkrižne vezave na receptorje TNF na površini celice.
For patients who received 25 mg twice weekly throughout the study, the PASI 75 response continued to improve between weeks 12 and 36. 
Pri bolnikih, ki so dobivali 25 mg dvakrat na teden ves čas študije, se je odziv PASI 75 med 12. in 36. tednom še naprej izboljševal.
These mean concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed in patients with juvenile idiopathic arthritis (treated with 0.4 mg/kg etanercept twice weekly, up to maximum dose of 50 mg per week). 
Te povprečne koncentracije pri bolnikih s pediatrično psoriazo v plakih so bile podobne koncentracijam, ki so jih opazili pri bolnikih z juvenilnim idiopatskim artritisom (zdravljenih z 0,4 mg/kg etanercepta dvakrat na teden, do največjega odmerka 50 mg na teden).
• To break the seal, bend the larger end down and then up until broken (see Diagram 13). 
Plombo prelomite tako, da upognete daljši del brizge navzdol in nato navzgor, dokler se ne prelomi (glejte sliko 13).
Do not use LIFMIOR 
Ne uporabljajte zdravila LIFMIOR
Patients weighing 62.5 kg or more, may be dosed using a fixed-dose pre-filled syringe or pre-filled pen. 
Bolnikom, ki tehtajo 62,5 kg ali več, lahko dajemo odmerke zdravila z napolnjeno injekcijsko brizgo ali napolnjenim injekcijskim peresnikom s stalnim odmerkom.
This section presents data from four randomised controlled trials in adults with rheumatoid arthritis, one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis, one study in adults with non-radiographic axial spondyloarthritis, four studies in adults with plaque psoriasis, three studies in juvenile idiopathic arthritis and one study in paediatric patients with plaque psoriasis. 
V tem poglavju so prikazani podatki iz štirih randomiziranih nadzorovanih preskušanj pri odraslih z revmatoidnim artritisom, ene študije pri odraslih s psoriatičnim artritisom, ene študije pri odraslih z ankilozirajočim spondilitisom, ene študije pri odraslih z radiografsko nezaznavnim aksialnim spondilartritisom, štirih študij pri odraslih s psoriazo v plakih, treh študij pri bolnikih z juvenilnim idiopatskim artritisom in ene študije pri otrocih s psoriazo v plakih.
Pancytopenia and aplastic anaemia 
Pancitopenija in aplastična anemija
Serious haematological, neurological and autoimmune reactions have also been reported. 
Poročali so tudi o pojavu resnih hematoloških, nevroloških in avtoimunskih neželenih učinkov.
Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. 
Zdravljenje aktivnega in progresivnega psoriatičnega artritisa pri odraslih, če je bil odziv na zdravljenje z imunomodulirajočimi antirevmatičnimi zdravili nezadosten.
This section presents data from three studies in juvenile idiopathic arthritis, one study in paediatric patients with plaque psoriasis, four studies in adults with rheumatoid arthritis, and four studies in adults with plaque psoriasis. 
V tem poglavju so prikazani podatki iz treh študij pri bolnikih z juvenilnim idiopatskim artritisom, ene študije pri otrocih s psoriazo v plakih, štirih študij pri odraslih z revmatoidnim artritisom in štirih študij pri odraslih s psoriazo v plakih.
In studies when adult patients received concurrent treatment with LIFMIOR plus anakinra, a higher rate of serious infections compared to LIFMIOR alone was observed and 2% of patients (3/139) developed neutropenia (absolute neutrophil count < 1000/mm3). 
V študijah, v katerih so odrasli bolniki sočasno prejemali zdravilo LIFMIOR in anakinro, so opažali večjo stopnjo resnih okužb v primerjavi s samim zdravilom LIFMIOR in pri 2 % bolnikov (3/139) se je pojavila nevtropenija (absolutna koncentracija nevtrofilcev < 1.000/mm